Finasteride Market By Product (1 mg, 5 mg), Application (Prostate Enlargement, Prostate Cancer, Scalp Hair Loss, Excessive Hair Growth, Hormone Therapy) & Region for 2024-2031

Finasteride Market Valuation – 2024-2031

Growing awareness and acceptance of male pattern baldness as a treatable issue is resulting in a broader populace looking for hair loss alternatives. Furthermore, advances in digital marketing and telemedicine have made it simpler for pharmaceutical businesses to reach out directly to potential customers rather than through traditional healthcare channel propelling the market growth surpassing USD 108.36 Million in 2023 and reaching USD 123.03 Million by 2031.

Furthermore, increasing research into Finasteride’s potential advantages in other illnesses, such as prostate cancer prevention, has increased its market potential. These reasons, taken together, contribute to Finasteride’s growing market presence and greater utilization as a therapeutic choice for both cosmetic and medicinal applications is expected to grow at a CAGR of about 1.60% from 2024 to 2031.

Finasteride MarketDefinition/ Overview

Finasteride is a 5-alpha reductase inhibitor that is primarily used to treat male pattern baldness and benign prostatic hyperplasia (BPH). It works by lowering levels of dihydrotestosterone (DHT), a hormone associated with prostate enlargement and hair loss. Finasteride aids in the treatment of BPH symptoms such as urinary hesitancy and frequent urination, while in male pattern baldness it reduces hair loss and increases hair growth. Finasteride are used off-label to treat hyperandrogenism symptoms such as hirsutism. Transgender women may benefit from the drug’s anti-androgen qualities when used with estrogen.

Finasteride is not suggested for women who are pregnant or may become pregnant. The Endocrine Society recommends the use of finasteride for hirsutism in premenopausal women. Looking ahead, Finasteride’s reach extends beyond these illnesses; ongoing research investigates its potential for avoiding prostate cancer and treating other androgen-related problems, indicating a bright future for this medicine in broader therapeutic applications.

Will Expanding Development of Compound Hair Care Treatment Growth of Finasteride Market?

The growing availability of compound hair care products is propelling the Finasteride Market by providing more comprehensive answers to hair loss. These therapies include numerous active chemicals, such as finasteride and minoxidil, to provide more efficacy than single-ingredient solutions. As a result, consumers looking for effective and versatile hair care solutions are increasingly turning to compound treatments, driving up demand for finasteride.

Innovation in the pharmaceutical and cosmetic industries also contributes to the growth of the Finasteride Market. Companies are investing in R&D to uncover novel combinations of active substances that will improve the effectiveness of hair loss therapies. Finasteride, which has been proven effective, is commonly incorporated in these innovative formulations, enticing both new and existing customers to these cutting-edge treatments.

The establishment of compound hair care treatments into telemedicine platforms bolsters the finasteride business. Telemedicine provides patients with a simple and inconspicuous way to obtain comprehensive hair loss treatments, including ones using finasteride. This enhanced accessibility, combined with the efficacy of compound therapies, enhances patient adherence and satisfaction, resulting in consistent growth in the Finasteride Market.

Rising clinical trials are revealing finasteride’s actual potential, accelerating market expansion. Healthcare practitioners are increasingly recognizing finasteride’s usefulness in treating benign prostatic hyperplasia and hair loss.

For instance, in November 2023, Mangoceuticals has expanded its male health product portfolio with the launch of Grow by MangoRx, a combined hair growth therapy. This new product combines biotin, vitamin D3, finasteride, and minoxidil to provide a holistic treatment for hair growth.

Will Increasing Side Effects of Sexual Dysfunction Hinder the Growth of the Finasteride Market?

The rising incidence of sexual dysfunction related with Finasteride is a major concern that will stymie market growth. Finasteride has been linked to sexual adverse effects such as decreased libido, erectile dysfunction, and decreased semen volume in certain users. These adverse effects can be particularly concerning since they have a direct influence on patients’ quality of life and psychological well-being, leading to reluctance to begin or continue taking the medicine. The occurrence of these adverse effects, while not universal, has sparked significant interest in both the medical profession and among patients, raising concerns about Finasteride’s risk-benefit ratio. The rising side effects of sexual dysfunction connected with Finasteride are undoubtedly a significant concern that could potentially hamper the expansion.

As patients and healthcare providers become more aware of these side effects, their opinions about Finasteride may evolve. The internet and social media have played an important role in spreading information about potential side effects, making patients more cautious. Online forums and patient advocacy groups have amplified personal tales of those who have experienced Finasteride’s sexual side effects, potentially discouraging new users. Furthermore, when healthcare providers become more aware of the hazards, they may be more cautious in prescribing Finasteride, preferring alternate treatments when possible. This increased awareness and caution may result in fewer prescriptions, having a direct impact on Finasteride’s market growth.

Also, regulatory authorities may establish stricter guidelines and cautions about the use of Finasteride, hurting its market. If regulatory authorities require more conspicuous warnings regarding the dangers of sexual dysfunction or more stringent post-market surveillance, the drug’s use may drop. Pharmaceutical companies may also face heightened scrutiny and legal battles over the drug’s side effects, which can be costly and hurt their market position. Such regulatory steps may dissuade doctors from prescribing Finasteride and patients from taking it, adding to a potential market decline.

The pharmaceutical business may respond by investing in R&D to lessen these side effects or inventing new formulations with fewer harmful effects. Advances in precision medicine may potentially enable better identification of individuals who are less prone to experience these adverse effects, sustaining the market for Finasteride within a subgroup of patients. Furthermore, comprehensive patient education and informed consent processes can assist manage expectations and minimize the incidence of side effects, potentially maintaining a portion of the market. Nonetheless, rising awareness and worry about sexual dysfunction side effects provide a significant impediment to the expansion of the Finasteride Market, necessitating proactive actions from pharmaceutical companies and healthcare providers to address these issues.

Category-Wise Acumens

Will Rising Demand for 5mg Dosage for Prostatic Hyperplasia (BOH) Drive the Finasteride Market?

The increasing demand for Finasteride 5 mg for benign prostatic hyperplasia (BPH) is expecting to drive the Finasteride Market. BPH is a common disorder in older men characterized by non-cancerous enlargement of the prostate gland, which causes urinary symptoms such as frequent urination, urine urgency, and incomplete bladder emptying. As the world population ages and life expectancy rises, so does the prevalence of BPH, resulting in a larger patient pool in need of appropriate treatment alternatives.

Finasteride at a dosage of 5 mg is shown to be an effective treatment for BPH. It acts by blocking 5-alpha-reductase, an enzyme that transforms testosterone into dihydrotestosterone (DHT), a hormone involved with prostate development. Finasteride helps shrink the prostate gland by lowering DHT levels, which relieves urinary symptoms and improves patients’ quality of life. Finasteride’s efficacy and relatively low side effect profile in treating BPH have made it a popular choice among both healthcare practitioners and consumers.

Rising awareness and acceptance of medical therapies for BPH are encouraging more people to seek pharmaceutical interventions such as Finasteride. As individuals become more aware of available treatment choices and more proactive in managing their health, the demand for drugs that can successfully relieve BPH symptoms, such as Finasteride, is projected to increase. Moreover, healthcare systems around the world are focusing on better managing chronic illnesses like BPH in order to improve patient outcomes and lower healthcare expenditures associated with consequences caused by untreated or poorly managed BPH.

Also, pharmaceutical companies are spend in R&D efforts to improve the formulation and administration of Finasteride for BPH therapy. This could include new dose forms, such as extended-release formulations or combination medicines that improve convenience, compliance, and efficacy. Such improvements would help to boost the market growth of Finasteride for BPH treatment, ensuring that it remains a key component of therapeutic methods for managing this common and painful illness in aging men.

However, the 1 mg category is the fastest-growing, owing to its efficacy in treating male pattern baldness, a disorder that affects a sizable proportion of the male population worldwide. The growing awareness and acceptability of hair loss therapies, combined with rising aesthetic concerns, is driving the rapid expansion of the 1 mg Finasteride Market.

Will Rising Cases of Scalp Hair Loss Fuel the Finasteride Market?

The increasing incidence of scalp hair loss is the potential to greatly boost the Finasteride industry. Male pattern baldness, also known as androgenetic alopecia, affects a large proportion of the male population worldwide, with the prevalence increasing as men age. Genetics, hormonal changes (particularly elevated levels of dihydrotestosterone or DHT), and lifestyle factors all play a role in this illness. As societal standards place more emphasis on personal appearance and youth, the psychological impact of hair loss motivates people to seek effective therapies.

Finasteride, particularly at a 1 mg dose (marketed as Propecia), is emerging as a top pharmacological choice for treating male pattern baldness. It works by blocking the enzyme 5-alpha-reductase, which decreases testosterone conversion to DHT, delaying hair loss and boosting hair growth. Finasteride’s success in clinical studies, combined with its tolerable side effect profile, makes it a popular choice among both patients and healthcare providers.

Furthermore, improvements in digital health platforms and telemedicine have increasing access to therapies such as Finasteride, allowing people to interact with healthcare experts remotely and get prescriptions more easily. This accessibility, combined with increasing awareness of hair loss therapies through media and internet forums increasing Finasteride’s potential market reach.

The increasing need for cosmetic solutions, as well as the normalization of hair loss therapies, all contribute to finasteride’s optimistic market forecast. Pharmaceutical companies continue to spend in research & development to improve formulations and satisfy patient-specific demands, hence boosting market growth. However, continued monitoring and understanding of possible side effects, such as sexual dysfunction, necessitate balanced patient education and regulatory oversight in order to maintain confidence in finasteride use.

Gain Access into Finasteride Market Report Methodology

Country/Region-wise

Will Rising Cases of Androgenic Alopecia in North America Drive the Finasteride Market?

Rising incidences of androgenic alopecia in North America are likely to considerably impact the finasteride industry. Androgenic alopecia, often known as male or female pattern baldness, is a common disorder in North America, affecting a considerable percentage of the population. As the prevalence of this problem rises, so will the demand for effective therapies like finasteride, which is well-known for its ability to decrease hair loss and promote hair growth.

Androgenic alopecia is becoming more common in North America as the population ages. As a larger proportion of the population ages, the prevalence of androgenic alopecia, which tends to increase with age, rises as well. Furthermore, lifestyle variables such as stress, poor food, and exposure to environmental toxins can worsen hair loss, increasing demand for therapies such as finasteride.

In addition to this, rising awareness of hair loss treatments, as well as the availability of improved healthcare solutions, are driving the growth of the Finasteride Market in North America. Patients are learning more about the therapy options available to them, particularly the efficacy of finasteride. This awareness, combined with the ease of access to healthcare professionals and prescription pharmaceuticals, is encouraging more people to seek treatment for androgenic alopecia, hence increasing the need for finasteride.

Furthermore, the substantial presence of pharmaceutical businesses in North America, together with ongoing research and development activities, is making finasteride more accessible and affordable. Major pharmaceutical companies are spending in clinical investigations and marketing activities to promote finasteride and broaden its usage. These efforts are expected to boost market demand by increasing product availability and consumer awareness.

Will Increasing Healthcare Investments in Asia-Pacific Propel the Finasteride Market?

Increasing healthcare investments in the Asia-Pacific area are expected to have a substantial impact on the Finasteride Market, however with notable differences from other regions. As Asia-Pacific countries see rapid economic development and urbanization, healthcare spending increases to improve access to quality medical treatments, including those for dermatological diseases like androgenic alopecia.

Healthcare Investments in Asia Pacific represents the region’s demographic shift, marked by aging populations and changing lifestyles. These variables contribute to an increased risk of androgenic alopecia, particularly in middle-aged and older adults. As people become more aware of cosmetic treatments and have more disposable means, there will be a greater demand for effective hair loss treatments like finasteride.

The region is seeing advances in healthcare infrastructure and technology, which are improving the delivery of medical services. Improved healthcare facilities, access to telemedicine, and increased availability of prescription drugs all contribute to a more favorable environment for treating chronic illnesses like androgenic alopecia. This infrastructure development promotes the growth of the Finasteride Market by improving access to healthcare providers and treatments.

Furthermore, government initiatives and healthcare reforms in Asia-Pacific countries are working to improve healthcare availability and cost. These reforms frequently involve initiatives to increase insurance coverage and reduce healthcare costs, making pharmaceuticals like finasteride more affordable to a larger population. Increased government support for healthcare infrastructure and services supports private-sector investment in medicines, which drives innovation and growth.

Competitive Landscape

The competitive landscape of the Finasteride Market is shaped by a variety of factors including patent expirations, generic competition, and regulatory policies. With the expiration of Merck’s patent on Propecia (finasteride) in many regions, numerous generic versions have entered the market, increasing competition and driving down prices. This has led to heightened competition among pharmaceutical companies producing generic finasteride, including smaller firms and regional players. Additionally, online pharmacies and telemedicine platforms are becoming significant distributors of finasteride, offering competitive pricing and convenience. Regulatory policies and approvals, such as those from the FDA and EMA, also play a critical role in shaping the market dynamics, influencing the availability and market entry of new generic formulations. The market is further influenced by marketing strategies, brand loyalty, and the efficacy of direct-to-consumer advertising, which collectively impact consumer choice and market share distribution.

Some of the prominent players operating in the Finasteride Market include

Merck, Teva Pharmaceuticals, Novartis, RelonChem, Reddy, Henan Topfond, Cipla, Actavis, Sandoz, Accord Pharmaceuticals.

Latest Developments

• In March 2024, Zydus Lifesciences Limited has received final FDA approval to commercialize its Finasteride and Tadalafil Capsules USP 5 mg/5 mg), the firm reported in an exchange filing on March 16.Notably, Zydus is the “first approved applicant” for Finasteride and Tadalafil Capsules, 5 mg/5 mg, according to section 505(j)(5)(B)(v)(III) of the FD&C Act, which qualifies for 180 days of Competitive Generic Therapy (CGT) exclusivity, according to its filing. This medication is used to treat benign prostatic hyperplasia and will be manufactured at Zydus’ formulation manufacturing plant in Gujarat’s Ahmedabad SEZ II, according to the company’s announcement.
• In August 2023, Happy Head recently released its most recent breakthrough in topical hair growth products. This combination, developed by dermatologists and hair restoration experts, infuses the strongest prescription-grade hair growth treatment into a liposomal substrate, allowing the medication to gradually release into hair follicles while reducing systemic absorption and associated adverse effects. It is the first product of its type to incorporate FDA-approved components into a lipid-based, mess-free composition. Happy Head’s Topical Finasteride and Minoxidil (Liposomal Formula) is a daily-use treatment intended to make treating hair loss easier.

Report Scope

Finasteride Market, By Category

Product

• 1 mg
• 5 mg

Application

• Prostate Enlargement
• Prostate Cancer
• Scalp Hair Loss
• Excessive Hair Growth
• Hormone Therapy
  1. Transgender
  2. Women

Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Research Methodology of Market Research